Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

ImmunityBio (IBRX) Amortization - Intangibles (2016 - 2021)

ImmunityBio (IBRX) has disclosed Amortization - Intangibles for 7 consecutive years, with -$23000.0 as the latest value for Q2 2021.

  • Quarterly Amortization - Intangibles rose 52.08% to -$23000.0 in Q2 2021 from the year-ago period, while the trailing twelve-month figure was -$836000.0 through Jun 2021, down 808.7% year-over-year, with the annual reading at -$858000.0 for FY2020, 28700.0% down from the prior year.
  • Amortization - Intangibles for Q2 2021 was -$23000.0 at ImmunityBio, up from -$384000.0 in the prior quarter.
  • The five-year high for Amortization - Intangibles was $42000.0 in Q2 2019, with the low at -$572000.0 in Q1 2017.
  • Average Amortization - Intangibles over 5 years is -$172823.5, with a median of -$81000.0 recorded in 2018.
  • The sharpest move saw Amortization - Intangibles soared 133.33% in 2019, then tumbled 3100.0% in 2020.
  • Over 5 years, Amortization - Intangibles stood at -$299000.0 in 2017, then skyrocketed by 72.91% to -$81000.0 in 2018, then skyrocketed by 85.19% to -$12000.0 in 2019, then crashed by 3100.0% to -$384000.0 in 2020, then skyrocketed by 94.01% to -$23000.0 in 2021.
  • According to Business Quant data, Amortization - Intangibles over the past three periods came in at -$23000.0, -$384000.0, and -$381000.0 for Q2 2021, Q4 2020, and Q3 2020 respectively.